Detection of neuron-derived cfDNA in blood plasma: a new diagnostic approach for neurodegenerative conditions.
Level 4 - case-series / case-control
Exploratory diagnostic case-control biomarker study comparing clinical patient groups and healthy controls.
PubMed 38020656 · doi:10.3389/fneur.2023.1272960
What was done
Researchers identified differential methylation regions (DMRs) distinguishing purified cortical neurons from blood cells to detect neuron-derived cell-free DNA (cfDNA) in blood plasma. They evaluated targeted sequencing at the identified DMR locus using plasma samples from patients with Alzheimer's disease (AD), patients with mild cognitive impairment (MCI) who either progressed or did not progress to AD, and healthy controls.
What was found
A cutoff of 5% neuron-derived cfDNA in blood plasma identified 100% of patients diagnosed with AD. The method also differentiated MCI patients who progressed to AD from those who did not, and separated patients with neurodegenerative disease from healthy controls. No exact participant numbers, specific sensitivity/specificity values, or confidence intervals were provided in the abstract.
Why it matters
If validated, measuring neuron-derived cfDNA methylation in blood could provide a minimally invasive, accessible screening and prognostic tool for neurodegenerative disease compared to invasive cerebrospinal fluid or tissue testing.
Limits
The abstract reports no sample sizes, demographic characteristics, or formal diagnostic test accuracy statistics (such as confidence intervals, AUC, or specific specificity percentages). The analysis was limited to a small set of loci and carries technical limitations inherent to PCR amplification and bisulfite conversion.
Cited by
- supports Cell-free DNA released from dying brain neurons enters the bloodstream and can be identified as neuron-derived using cell-type-specific epigenetic methylation marks.